TY - JOUR
T1 - Risk of recurrent stroke for Asian stroke patients treated with non-vitamin K antagonist oral anticoagulant and warfarin
AU - Lin, Sheng Feng
AU - Lu, Yi Hsuan
AU - Bai, Chyi Huey
N1 - Funding Information:
Each author contributed to the conception and design of the study, acquisition, analysis, and interpretation of data. SF Lin wrote the first draft of the manuscript. The Ministry of Science and Technology (MOST) is s the governmental entity. The funder (MOST) had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Ministry of Science and Technology (MOST) and the reference number was MOST 107-2314-B-038-072-MY3.
Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Ministry of Science and Technology (MOST) and the reference number was MOST 107-2314-B-038-072-MY3.
Publisher Copyright:
© The Author(s), 2020.
PY - 2020
Y1 - 2020
N2 - Aim: The aim of this study was to establish whether non-vitamin K antagonist oral anticoagulants (NOACs) are superior to warfarin in preventing stroke recurrence for atrial fibrillation (AF) patients with an ischemic or hemorrhagic stroke at the baseline. Methods: From 1 January 2009 to 31 December 2017, stroke patients with AF treated with oral anticoagulants in the National Health Insurance Research Database in Taiwan were enrolled. The study was retrospective cohort design. Outcome measures were ischemic and hemorrhagic stroke recurrence. The Cox proportional hazard model was used to obtain the hazard ratio (HR). Results: In total, 39,840 stroke patients with AF treated with NOAC and 42,583 treated with warfarin were identified. NOACs were superior to warfarin in preventing all recurrent stroke [adjusted HR: 0.67, 95% confidence interval (CI), 0.63–0.71, p < 0.001]. Results for the ischemic stroke population were the same as that for all types for stroke (adjusted HR: 0.66, 95% CI, 0.62–0.70, p < 0.001). For the hemorrhagic stroke population, NOACs were equivalent to warfarin in preventing ischemic stroke (adjusted HR: 1.11, 95% CI, 0.86–0.43, p < 0.001), but NOACs were superior to warfarin in preventing hemorrhagic stroke (adjusted HR: 0.64, 95% CI, 0.55–0.74, p < 0.001). Conclusions: NOACs were generally superior to warfarin in terms of efficacy and safety in previous stroke patients. The robustness of our findings was verified and should add new information to current recommendations for Asian stroke patients in selecting NOACs.
AB - Aim: The aim of this study was to establish whether non-vitamin K antagonist oral anticoagulants (NOACs) are superior to warfarin in preventing stroke recurrence for atrial fibrillation (AF) patients with an ischemic or hemorrhagic stroke at the baseline. Methods: From 1 January 2009 to 31 December 2017, stroke patients with AF treated with oral anticoagulants in the National Health Insurance Research Database in Taiwan were enrolled. The study was retrospective cohort design. Outcome measures were ischemic and hemorrhagic stroke recurrence. The Cox proportional hazard model was used to obtain the hazard ratio (HR). Results: In total, 39,840 stroke patients with AF treated with NOAC and 42,583 treated with warfarin were identified. NOACs were superior to warfarin in preventing all recurrent stroke [adjusted HR: 0.67, 95% confidence interval (CI), 0.63–0.71, p < 0.001]. Results for the ischemic stroke population were the same as that for all types for stroke (adjusted HR: 0.66, 95% CI, 0.62–0.70, p < 0.001). For the hemorrhagic stroke population, NOACs were equivalent to warfarin in preventing ischemic stroke (adjusted HR: 1.11, 95% CI, 0.86–0.43, p < 0.001), but NOACs were superior to warfarin in preventing hemorrhagic stroke (adjusted HR: 0.64, 95% CI, 0.55–0.74, p < 0.001). Conclusions: NOACs were generally superior to warfarin in terms of efficacy and safety in previous stroke patients. The robustness of our findings was verified and should add new information to current recommendations for Asian stroke patients in selecting NOACs.
KW - apixaban
KW - dabigatran
KW - edoxaban
KW - ischemic stroke
KW - recurrent event
KW - rivaroxaban
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85096897453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096897453&partnerID=8YFLogxK
U2 - 10.1177/2040622320974853
DO - 10.1177/2040622320974853
M3 - Article
AN - SCOPUS:85096897453
VL - 11
JO - Therapeutic Advances in Chronic Disease
JF - Therapeutic Advances in Chronic Disease
SN - 2040-6223
ER -